2013
Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA
Rae JM, Regan MM, Thibert JN, Gersch C, Thomas D, Leyland-Jones B, Viale G, Pusztai L, Hayes DF, Skaar T, Van Poznak C. Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA. Journal Of The National Cancer Institute 2013, 105: 1332-1334. PMID: 23958736, PMCID: PMC3888280, DOI: 10.1093/jnci/djt204.Peer-Reviewed Original ResearchConceptsCYP2D6 genotypeCYP2D6 metabolic phenotypeBreast cancer patientsMetabolic phenotypeAnti-estrogen tamoxifenCancer clinical trialsCancer patientsClinical trialsTumor alterationsGermline DNAConflicting resultsPatientsTumorsTissue sourcesGenotype association studiesConcordanceGenotypesPhenotypeAssociation studiesFFPETTamoxifenEndoxifenWBCCYP2D6Trials
2011
Effect of CYP2D6 polymorphisms on breast cancer recurrence
Morrow PK, Serna R, Broglio K, Pusztai L, Nikoloff DM, Hillman GR, Fontecha M, Li R, Michaud L, Hortobagyi G, Gonzalez‐Angulo A. Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer 2011, 118: 1221-1227. PMID: 21823108, DOI: 10.1002/cncr.26407.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarcinomaCase-Control StudiesCohort StudiesCytochrome P-450 CYP2D6Cytochrome P-450 CYP2D6 InhibitorsEnzyme InhibitorsFemaleFollow-Up StudiesGenetic Predisposition to DiseaseHumansMastectomyMiddle AgedNeoplasm Recurrence, LocalPolymorphism, GeneticTamoxifenConceptsEarly breast cancerBreast cancer recurrenceAdjuvant tamoxifen therapyCancer recurrenceTamoxifen therapyMedical historyCYP2D6 genotypeTexas MD Anderson Cancer CenterFresh frozen tumor samplesCytochrome P450 2D6 polymorphismMD Anderson Cancer CenterBreast cancer patientsRisk of recurrenceCase-control studyAnderson Cancer CenterPatient's medical historyFrozen tumor samplesAdjuvant tamoxifenAdjuvant therapyConcomitant medicationsPatient characteristicsAmpliChip CYP450 TestCYP2D6 metabolismDisease recurrenceCancer Center